AKT1 and neoplasm: Quantitative proteomics identified that synephrine exhibited anticancer effects through inactivating AKT and ERK pathways by downregulating the protein expression of Galectin-3, which was further validated by western blot and qRT–PCR in ESCC cells and tumour xenografts in nude mice (Xu et al., 2018).